Agenus Inc., a leader in immuno-oncology, has announced that four abstracts related to their botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, to be held in Berlin, Germany, from October 17-21, 2025. The presentations will highlight the clinical progress of these therapies in treating refractory metastatic solid tumors across five tumor types. The key event is an oral presentation focusing on emerging survival plateaus from a study involving 343 evaluable patients, to be presented by Dr. Michael Gordon from HonorHealth Research Institute, USA, on October 17. Additional poster presentations will cover data from studies on cervical cancer, MSS metastatic colorectal cancer, and non-melanoma skin cancers, showcasing the potential of these immunotherapy combinations in treating difficult-to-treat cancers. These results will be presented in the future at the specified dates and times during the congress.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.